Welcome to Allegro Ophthalmics
Accelerated Innovation. Needed Intervention.
Answering an Unmet Need in DME
Allegro’s lead investigational drug, Luminate®, contains a unique molecule that binds to integrins – a special class of cell surface receptors that plays diverse roles in cellular function. With a new method of action that works differently than existing therapies, Luminate® could help 50 percent of DME patients who don’t respond sufficiently to achieve functional vision.1
Allegro’s lead investigational drug Luminate® has been shown to significantly reduce the current burden of intravitreal injections and to be a viable option for patients with wet age-related macular degeneration and diabetic macular edema.
- Shown to significantly reduce the current burden of intravitreal injections
- A viable option for patients with DME
- Blocks the pathways that cause retinal damage in DME
Only Luminate® stabilizes the retina by suppressing multiple pathways that contribute to DME, helping patients achieve functional vision1
- It has been proven to help patients achieve equivalent vision gain as anti-VEGF treatment, with HALF THE NUMBER OF TOTAL INJECTIONS1
References: 1. Data on file.